In the era of biomarker-driven personalized cancer therapy, several biomarkers have been proposed as prognostic and predictive factors in different cancers, such as KIT mutations in gastrointestinal stromal tumors, EGFR mutations in lung cancer, and HER2 overexpression in breast cancer [16]. Here, KIT is linked to cancer.